Diabetes drug shows promise for rare immune disorder
NCT ID NCT05960617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether empagliflozin, a diabetes drug also known as Jardiance, can help people with glycogen storage disease type Ib (GSD-1b). GSD-1b causes low neutrophil counts, leading to frequent infections and bowel inflammation. The study gives empagliflozin orally to patients aged 1 to 50 years and tracks changes in neutrophil levels, infection rates, and inflammatory bowel disease activity over one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- empagliflozin (Jardiance)
- What this could lead to
- If it works, this could offer a new treatment option for people with GSD-1b to improve immune function and reduce infections and bowel inflammation.
- What could go wrong
- This is an early phase 2 trial with a small number of participants. The drug may cause low blood sugar or other side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLYCOGEN STORAGE DISEASE TYPE IB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200092, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.